Arteriosclerosis treatment

Carpenter, R. H. Xargeted oxidative therapeutic formulation for arteriosclerosis treatment. PCX Int. Appl. WO 2002078623, 2002 Chem. Abstr. 2002, 137, 284357. 

Peripheral vasodilating drugs are chiefly used in the treatment of peripheral vascular diseases, such as arteriosclerosis obliterans, Raynaud s phenomenon, and spastic peripheral vascular disorders. Short-term use is rarely beneficial or permanent. Improvement, if it occurs, takes place gradually during weeks of therapy. 

FRUEBis J, GONZALEZ v, siLVESTRE M and PALiNSKi w (1997) Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early sihsro genss.is, Arteriosclerosis, Thrombosis and Vascular Biology 17, 1289-302. 

Aside from its use as an antimalarial compound, quinine is used for the prevention and treatment of nocturnal leg muscle cramps, especially those resulting from arthritis, diabetes, thrombophlebitis, arteriosclerosis, and varicose veins. 

It is indicated in arteriosclerosis, as adjunct in treatment of hypertension, diabetes and obesity. 

Of 34 Japanese patients with diabetes and chronic hepatitis, 18 were given glycyrrhizin 240-525 mg for over 1 year (447). This resulted in a significant lowering of total testosterone concentrations and increased arteriosclerotic plaque formation. The authors suggested that glycyrrhizin treatment was an independent risk factor for arteriosclerosis. The testosterone lowering effect of liquorice has been confirmed in another trial (448). 

Native Americans used hawthorn as a diuretic for kidney and bladder disorders and to treat stomachaches, stimulate appetite, and improve circulation. The flowers and berries have astringent properties and can be used to treat sore throats in the form of haw jelly or haw marmalade. Today, hawthorn is promoted for the treatment of heart failure, hypertension, arteriosclerosis, angina pectoris, Buerger s disease, paroxysmal tachycardia, heart valve murmurs, sore throat, skin sores, diarrhea, and abdominal distention. 

Polyunsaturated fatty acids (PUFAs) have various physiological functions and are widely used as pharmaceuticals, neutraceuticals, and as food additives. The ethyl ester of eicosapentaenoic acid (EPA) has been used for the treatment of arteriosclerosis and hyperlipemia since 1991 in Japan (Hara, 1993). DHA possesses not only similar physiological activities to those of EPA, but also an important function in the brain and retina (Hung, 2007). In addition, DHA accelerates the growth of preterm infants as does arachidonic acid (Carlson et al., 1993 Lanting et al., 1994). From these reasons, DHA ethyl ester (DHAEE) is currently expected to be used as a medicine, and the development of the purification methods is desired. 

Medicaments Comprising These Compounds and Their Use H. Glombik et al, US Patent 6,992,067 (January 31, 2006) Assignee Aventis Pharma Deutschland GmbH Utility Treatment of Arteriosclerosis... 

In earlier investigations by the authors (2,3), pyridine-, (I), and 1, l-dioxo-2,3,4,5-tetrahydro-lH-benzo[b]thiepine derivatives, (II), respectively, were prepared having limited bioabsorption while remaining effective in the treatment of arteriosclerosis. 

In conjunction with a statin such as simvastatin, l,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanol derivatives, (IV), prepared by Kirsch (5) were effective as hypolipidemic agents in the treatment of arteriosclerosis. 

Morpholin-4-yl-piperizyl) quinazoline derivatives, (I), prepared by Kanter (2) were effective as kinase phosphorylation inhibitors and used in the treatment of proliferative diseases such as arteriosclerosis, vascular reobstruction after percutaneous coronary angioplasty, and bypass operation cell-proliferative. Quinazoline derivatives, (n), prepared by Lambert (3) were effective against the Src family of nonreceptor tyrosine kinases inhibitors and used in the treatment of uncontrolled cellular proliferation. 

Vitamin E is the common name for o-a-tocopherol and is an oily liquid at room temperature and is also an antioxidant. Alfacalcidol, a dehydroxy derivative of calcitriol, is formulated as a solution in a mixture of sesame oil and a-tocopherol in 0.25 pg, 0.5 pg, and 1.0 pg One-Alpha soft gelatin capsules. Ethyl icosapen-tate is used in the treatment of hyperlipidemia and arteriosclerosis obliterans, and exists as a liquid at ambient room temperature that is formulated as a solution in a-tocopherol in 300 mg Epadel soft gelatin capsules. 

Ginsenoside Rgi had no effect on arachidonate metabolism, but it did reduce the elevation of cytosolic free calcium concentration [Ca2+]i shown in the second phase (Ca2+ influx) induced by adrenaline and thrombin "Fig. (37)". The results suggest that ginsenoside Rgl in red ginseng roots may be effective as a drug for the treatment of arteriosclerosis and thrombosis. 

Stilbenes and stilbene oligomers have a variety of antibacterial, antifungal and pharmacological properties [122,132-134], including possible beneficial effects on human health [135], In fact, stilbenes have been shown to be effective in the treatment of diseases such as hyperlipidemia, arteriosclerosis, and allergic and inflammatory diseases... 

Properties Red, rhomboid crystals. Mp 285C. Soluble in pyridine and dilute sodium hydroxide slightly soluble in water and organic solvents. Combustible. Use Experimental treatment of arteriosclerosis by increasing oxygen diffusion through arterial wahs, thus decreasing buildup of cholesterol. 

The analgesic (5-ethoxy-2--dimethylaminomethyl-3-methylquinazoIin-4-one and 4,2 -thienyIquinazolines ), antithrombic and anticoagulant (2-vinyl-l,4-dihydroquinazolines), and antifibrillatory (l-aminoacyl-1,2-dihydroquinazolin-4-ones) action of quinazoline derivatives were patented, and 2-phenoxycarbonyloxymethyl-3-substituted-quinazolin-4-ones were potentially useful drugs for the treatment of arteriosclerosis. The effects of Quinazodine (118) as a cardiac stimulant and its hemodynamic... 

Since Johann Lobstein first coined the term arteriosclerosis, or hardening of the arteries in 1833, to the Framingham Study which began in 1948 (42), to the isolation of mevastatin by Akira Endo in 1976 (43), and on to the publication of the Scandinavian Simvastatin Survival Study (4S) in 1994 (44), cholesterol levels have emerged as perhaps the most potent modifiable risk factor in the treatment of chronic ischemic heart disease. Genetic disorders such as homozygous familial hypercholesterolemia where severe atherosclerosis is present by early adolescence have helped clarify the importance of LDL cholesterol in the pathogenesis of atherosclerosis. 

---